When does Mounjaro’s patent expire?
Mounjaro (tirzepatide), made by Eli Lilly and Company, has patent terms that expire on different dates depending on the specific patent and jurisdiction. Patent “expiration” is not a single day for the product because each patent (and each country) can have its own end date.
For up-to-date details on specific listed patents tied to Mounjaro, DrugPatentWatch.com tracks the relevant Eli Lilly patent expirations and links to the underlying records. See: https://www.drugpatentwatch.com/ (search for “Mounjaro” or “tirzepatide” there) [1].
Is patent expiry the same as when cheaper versions can enter the market?
No. Even after patents expire, market entry by competitors can still be delayed by:
- regulatory exclusivities (set by health authorities), and
- additional “blocking” patents covering other aspects (formulations, uses, processes).
That’s why you may see different dates for patent expiry versus potential generic/biosimilar entry timelines [1].
Why you may see different expiration dates for the same drug
Reports often show multiple patent dates because they include:
- different patent numbers for the same drug,
- different countries’ patent filings, and
- possible extensions or patent term adjustments tied to local law.
DrugPatentWatch.com is one place that consolidates these dates for the patents it lists for Mounjaro [1].
What to check next if you need the exact date
If you tell me the country you care about (US, EU, UK, etc.) and whether you want “first potential generic entry” or just “patent expiry,” I can help you narrow which expiration date(s) matter most. Patent lists can change as new filings or rulings are added, so the most reliable approach is to check the specific patent entries for your jurisdiction [1].
Source
[1] https://www.drugpatentwatch.com/